bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2018: F J
2017: D N O S A J J M A M F

 
  Other news for:
Skin Diseases
 Resources from HONselect
Stem Cell Transplant Shows Promise for Immune Disorder Scleroderma

By Mary Elizabeth Dallas

WEDNESDAY, Jan. 3, 2018 (HealthDay News) -- Stem cell transplants could offer new hope for people with a severe form of scleroderma -- a debilitating and deadly condition that affects the immune system, a new study suggests.

"Scleroderma hardens the skin and connective tissues and, in its severe form, leads to fatal organ failure, most often the lungs," said the study's lead author, Dr. Keith Sullivan. He is a professor of medicine and cellular therapy at Duke University Medical Center.

"In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority," Sullivan said in a hospital news release.

Drugs to suppress the immune system are the standard of care in the United States for scleroderma with internal organ involvement, according to the researchers. Their study tested the effectiveness of stem cell transplant along with high-dose chemotherapy and whole-body radiation to treat the disease. The study was funded by the U.S. National Institutes of Health.

For the study, 75 people with scleroderma were randomly assigned to receive one of two treatments. Roughly half of the group received a stem cell transplant designed to destroy their defective immune system and replace it with their own treated blood stem cells. The other half received 12 months of conventional immune-suppressing treatment.

After 10 years, survival was better among those who underwent chemotherapy, whole-body radiation and a stem cell transplant, the study found. People in this group also had less need for immune-suppressing drugs after their transplant.

"These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable," Sullivan said.

The researchers noted, though, that stem cell transplant was riskier. It was associated with more serious side effects, such as low blood counts, infections and death, the study found.

"Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease," Sullivan said.

"These advances show the value of medical research and clinical trials in finding better therapies to advance health," he added.

The study was scheduled for publication in the Jan. 4 issue of the New England Journal of Medicine.

More information

The American College of Rheumatology has more on scleroderma.

SOURCE: Duke University Medical Center, news release, Jan. 3, 2018

Copyright © 2018 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=729838

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Transplants
Stem Cells
Cells
Immunologic Diseases
Therapeutics
Drug Therapy
Immune System
Blood
Research Personnel
Specialty Chemicals and Products
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact